Drs Ursula A. Matulonis and Immaculata De Vivo discuss the epidemiology of endometrial cancer and how clinicians can use information about risk factors.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s3-ep6-2026a10006ig. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

Cancer Stat Facts: Uterine Cancer https://seer.cancer.gov/statfacts/html/corp.html

Risk Prediction Models for Endometrial Cancer: Development and Validation in an International Consortium https://pubmed.ncbi.nlm.nih.gov/36688725/

Genome-wide Association Study of Endometrial Cancer in E2C2 https://pubmed.ncbi.nlm.nih.gov/24096698/

Projected Trends in the Incidence and Mortality of Uterine Cancer in the United States https://pubmed.ncbi.nlm.nih.gov/40589281/

Understanding Risk Factors for Endometrial Cancer in Young Women https://pubmed.ncbi.nlm.nih.gov/39235934/

Association Between Metabolic Syndrome and Endometrial Cancer Risk: A Systematic Review and Meta-analysis of Observational Studies https://pubmed.ncbi.nlm.nih.gov/32439832/

Cigarette Smoking and Endometrial Cancer Risk: Observational and Mendelian Randomization Analyses https://pubmed.ncbi.nlm.nih.gov/35900194/

Physical Activity and Risk of Endometrial Adenocarcinoma in the Nurses' Health Study https://pubmed.ncbi.nlm.nih.gov/24213924/

Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers https://pubmed.ncbi.nlm.nih.gov/31116674/

Type I and II Endometrial Cancers: Have They Different Risk Factors? https://pubmed.ncbi.nlm.nih.gov/23733771/

Differential Trends in Rising Endometrial Cancer Incidence by Age, Race, and Ethnicity https://pubmed.ncbi.nlm.nih.gov/36625534/

Harvard Radcliffe Institute. Podcast Episode 208: Kindness—It’s Good for You! December 12, 2024. Interview with Immaculata De Vivo and Daniel Lumera, authors of “The Biology of Kindness: Six Daily Choices for Health, Well-Being, and Longevity.” Accessed May 13, 2026. https://www.radcliffe.harvard.edu/news-and-ideas/episode-208-kindness-it-s-good-for-you

Research Project—Cooperative Agreements (U01) https://grants.nih.gov/funding/activity-codes/u01

Center for Inherited Disease Research https://cidr.jhmi.edu/

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Drs Ursula A. Matulonis and Marisa R. Nucci discuss the future of AI and pathology and how genetics and genomics play a role in the diagnosis of endometrial cancer.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s3-ep5-2026a10006if. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

WHO Classification of Tumours Online https://tumourclassification.iarc.who.int/welcome/

The Cancer Genome Atlas Program (TCGA) https://www.cancer.gov/ccg/research/genome-sequencing/tcga

TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/36232987/

FIGO Staging of Endometrial Cancer: 2023 https://pubmed.ncbi.nlm.nih.gov/37337978/

The Desert Immune Phenotype in Endometrial Carcinoma: A Distinct Subgroup With Poor Prognosis and Targetable Mutations https://pubmed.ncbi.nlm.nih.gov/41967711/

Controversies in the Management of Serous Tubal Intra-Epithelial Carcinoma Lesions of the Fallopian Tube https://www.international-journal-of-gynecological-cancer.com/article/S1048-891X(25)00192-6/fulltext

Comparative Modeling of Recent and Projected Trends in the Incidence and Mortality of Uterine Cancer https://pubmed.ncbi.nlm.nih.gov/41643197/

Current Prognostic and Predictive Biomarkers for Endometrial Cancer in Clinical Practice: Recommendations/Proposal From the Italian Study Group https://pubmed.ncbi.nlm.nih.gov/35463299/

Application of Artificial Intelligence in Gynecologic Cancers: A Bibliometric Analysis https://pubmed.ncbi.nlm.nih.gov/41585300/

Uterine Leiomyosarcoma https://pubmed.ncbi.nlm.nih.gov/35173990/

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Drs Ursula A. Matulonis and Stephanie Lheureux discuss the importance of investigator-initiated clinical trials in endometrial cancer, research on carcinosarcoma, and ctDNA.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s3-ep4-2026a10006ie. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

Advances in Antibody-Drug Conjugates for Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/40111079/

TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/36232987/

Translational Randomized Phase II Trial of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent, or Metastatic Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/35288469/

Elucidating Divergent Biology in Uterine Carcinosarcoma https://pubmed.ncbi.nlm.nih.gov/40850250/

The Immune Microenvironment in Endometrial Carcinoma: Mechanisms and Therapeutic Targeting https://pubmed.ncbi.nlm.nih.gov/40746533/

Epithelial-Mesenchymal Transition Orchestrates Tumor Microenvironment: Current Perceptions and Challenges https://pubmed.ncbi.nlm.nih.gov/40176117/

Comparative Modeling of Recent and Projected Trends in the Incidence and Mortality of Uterine Cancer https://pubmed.ncbi.nlm.nih.gov/41643197/

Genomic Landscape of ctDNA and Real-World Outcomes in Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/39417689/

Targeting CDK2 for Cancer Therapy https://pubmed.ncbi.nlm.nih.gov/40802510/

PYNNACLE Phase II Trial Assessing Rezatapopt (PC14586), a Selective p53 Reactivator, in Patients With Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation https://www.gynecologiconcology-online.net/article/S0090-8258%2825%2900347-6/abstract

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Drs Ursula Matulonis and Jessica St. Laurent discuss endometrial cancer research, funding, early detection, and treatment, including the impact of GLP-1 receptor agonists.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s3-ep3-2026a10006id. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

Hereditary Breast and Ovarian Cancer (HBOC): Review of Its Molecular Characteristics, Screening, Treatment, and Prognosis https://pubmed.ncbi.nlm.nih.gov/32862296/

Shifted Assembly and Function of mSWI/SNF Family Subcomplexes Underlie Targetable Dependencies in Dedifferentiated Endometrial Carcinomas https://pubmed.ncbi.nlm.nih.gov/41116019/

Cancer Statistics, 2026 https://pubmed.ncbi.nlm.nih.gov/41528114/

Tirzepatide as an Innovative Treatment Strategy in a Pre-Clinical Model of Obesity-Driven Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/39388742/

Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/38967919/

GLP-1 Receptor Agonists Plus Progestins and Endometrial Cancer Risk in Nonmalignant Uterine Diseases https://pubmed.ncbi.nlm.nih.gov/41665904/

TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives https://pubmed.ncbi.nlm.nih.gov/36232987/

Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome (SCREEN-CUP) https://clinicaltrials.gov/study/NCT07220239

Circulating Tumor DNA in Endometrial Cancer: Clinical Significance and Implications https://pubmed.ncbi.nlm.nih.gov/39955181/

PTEN Mutations as Predictive Marker for the High-Grade Endometrial Cancer Development in Slovak Women https://pubmed.ncbi.nlm.nih.gov/36592448/

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Drs Ursula A. Matulonis and David G. Mutch discuss past and present endometrial cancer research, including the Route 66 SPORE.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s3-ep2-2026a10006ic. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

Route 66 Endometrial Cancer SPORE https://dctd.cancer.gov/research/spores/state/wustl-endometrial

Final Analysis of RTOG 9708: Adjuvant Postoperative Irradiation Combined With Cisplatin/Paclitaxel Chemotherapy Following Surgery for Patients With High-Risk Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/16545437/

Pelvic Radiation With Concurrent Chemotherapy Compared With Pelvic and Para-Aortic Radiation for High-Risk Cervical Cancer https://pubmed.ncbi.nlm.nih.gov/10202164/

Surgical-Pathological Findings in Type 1 and 2 Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study on GOG-210 Protocol https://pubmed.ncbi.nlm.nih.gov/28392124/

GOG Foundation https://www.gog.org/

The Latest Updates in Translational Science at NRG Oncology (October 2025) https://www.nrgoncology.org/Home/News/Post/the-latest-updates-in-translational-science-at-nrg-oncology-october-2025/

Adjuvant Chemotherapy Plus Radiation for Locally Advanced Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/31189035/

Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post-Hoc Analysis by Molecular Classification From a Randomised Phase 3 Trial https://pubmed.ncbi.nlm.nih.gov/40921169/

FIGO Staging of Endometrial Cancer: 2023 https://pubmed.ncbi.nlm.nih.gov/37337978/

Practical Guidance for Assessing and Reporting Lymphovascular Space Invasion (LVSI) in Endometrial Carcinoma https://pubmed.ncbi.nlm.nih.gov/38937066/

Surgical Pathologic Spread Patterns of Endometrial Cancer. A Gynecologic Oncology Group Study https://pubmed.ncbi.nlm.nih.gov/3652025/

Integrated Genomic Characterization of Endometrial Carcinoma https://pubmed.ncbi.nlm.nih.gov/23636398/

AXL Inhibition Improves the Therapeutic Efficacy of Trastuzumab in High-Risk Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/41270342/

Patient-Derived Xenograft Mouse Models: A High Fidelity Tool for Individualized Medicine https://pubmed.ncbi.nlm.nih.gov/30655732/

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Drs Ursula A. Matulonis and Leif W. Ellisen discuss endometrial cancer and ADCs, including resistance mechanisms, ADC sequencing, what's exciting in the field, and novel payloads.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s2-ep6-2026a10008nk. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

The Clinical Landscape of Antibody-Drug Conjugates in Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/39074933/

FDA Grants Accelerated Approval to Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HER2-Positive Solid Tumors https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2

Mechanisms of Resistance to Antibody-Drug Conjugates https://pubmed.ncbi.nlm.nih.gov/36831621/

TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients With Metastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/39745368/

Single-Cell Analysis Technologies for Cancer Research: From Tumor-Specific Single Cell Discovery to Cancer Therapy https://pubmed.ncbi.nlm.nih.gov/37900181/

Spatial Transcriptomics for Tumor Heterogeneity Analysis https://pubmed.ncbi.nlm.nih.gov/35899203/

Exploring Circulating Tumor DNA (CtDNA) and Its Role in Early Detection of Cancer: A Systematic Review https://pmc.ncbi.nlm.nih.gov/articles/PMC10516512/

Current and Emerging Prognostic Biomarkers in Endometrial Cancer https://pubmed.ncbi.nlm.nih.gov/35530346/

Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer https://pubmed.ncbi.nlm.nih.gov/34404686/

Antibody-Drug Conjugate Sacituzumab Govitecan Enables a Sequential TOP1/PARP Inhibitor Therapy Strategy in Patients With Breast Cancer https://pubmed.ncbi.nlm.nih.gov/38709212/

Antibody-Drug Conjugates as Targeted Therapy for Treating Gynecologic Cancers: Update 2025 https://pubmed.ncbi.nlm.nih.gov/39480912/

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Drs Ursula A. Matulonis and Joyce F. Liu discuss targeting DNA damage and repair and replication stress in endometrial cancer.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-endometrial-cancer-s2-ep5-2026a10008nd. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Endometrial Carcinoma https://emedicine.medscape.com/article/254083-overview

Exploiting Replicative Stress in Gynecological Cancers as a Therapeutic Strategy https://pubmed.ncbi.nlm.nih.gov/32571890/

Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling Into Place https://pubmed.ncbi.nlm.nih.gov/29653955/

WEE1 Inhibition in Cancer Therapy: Mechanisms, Synergies, Preclinical Insights, and Clinical Trials https://pubmed.ncbi.nlm.nih.gov/40187712/

Phase 2 Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma https://pubmed.ncbi.nlm.nih.gov/33705205/

ADAGIO: A Phase 2b, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.TPS5612

Azenosertib Monotherapy Yields Encouraging Responses in Cyclin E1+ Proc https://www.cancernetwork.com/view/azenosertib-monotherapy-yields-encouraging-responses-in-cyclin-e1-proc

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase 3 Duo-E Trial https://pubmed.ncbi.nlm.nih.gov/37864337/

Homologous Recombination Deficiency: Concepts, Definitions, and Assays https://pubmed.ncbi.nlm.nih.gov/35274707/

A Replication Stress Biomarker Is Associated With Response to Gemcitabine vs Combined Gemcitabine and ATR Inhibitor Therapy in Ovarian Cancer https://pubmed.ncbi.nlm.nih.gov/34552099/

Abstract B144: Discovery and Preclinical Evaluation of Novel Oral WEE1 Degraders https://aacrjournals.org/mct/article/22/12_Supplement/B144/730300/Abstract-B144-Discovery-and-preclinical-evaluation

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.